LARRY LIPSHULTZ to Penile Induration
This is a "connection" page, showing publications LARRY LIPSHULTZ has written about Penile Induration.
Connection Strength
2.745
-
Clinical Significance of Shortened Penile Length and Alterations in Penile Length Following Treatment for Peyronie's Disease. Sex Med Rev. 2022 07; 10(3):409-420.
Score: 0.716
-
Objective Assessments of Peyronie's Disease. Sex Med Rev. 2018 07; 6(3):438-445.
Score: 0.529
-
Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015 Oct; 116(4):650-6.
Score: 0.437
-
Minimally invasive treatment of Peyronie's disease: evidence-based progress. BJU Int. 2014 Jul; 114(1):16-24.
Score: 0.411
-
Long-Term Satisfaction With Collagenase Clostridium Histolyticum for Peyronie's Disease: Clinical Predictors and Side Effect Profile. Urol Pract. 2025 01; 12(1):168-175.
Score: 0.208
-
Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease. J Urol. 2020 06; 203(6):1191-1197.
Score: 0.151
-
Increased Risk of Incident Disease in Men with Peyronie's Disease: Analysis of U.S. Claims Data. J Sex Med. 2018 06; 15(6):894-901.
Score: 0.135
-
Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012 Jun; 187(6):2268-74.
Score: 0.088
-
Correlation of degree of penile curvature between patient estimates and objective measures among men with Peyronie's disease. J Sex Med. 2009 Mar; 6(3):862-5.
Score: 0.071